Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by DryBoneson Feb 17, 2018 2:17am
230 Views
Post# 27576772

RE:for the losers trying to discredit the pg trial

RE:for the losers trying to discredit the pg trialYes, it is True what GoBBs says.  

However,  the news release  also said, and I quote,"This means that we are on target for an expected commercial launch of plasminogen in the USA mid-next year.  This was stated in OCT. 2016.  Meaning: commercial launch mid-2017.  

We are delayed and by april we will be 2 months shy of being a year late.  So Mr. Gobbs, this is why the whinning, b-itcing etc.  It is due to general lack of reliability of statements made by PLI management.  This does reflect badly on the share price.
It is not due to our whinning, it is due to poor management.

I for one am ready to forgive and forget should management get that approval soon.


Read more at https://www.stockhouse.com/news/press-releases/2016/10/26/prometic-s-plasminogen-meets-primary-and-secondary-end-points-in-pivotal-phase#oShcW4Hu7iOwJVSM.99
Bullboard Posts